Last update Sept. 14, 2022
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
أوكسابروزين is Oxaprozin in Arabic.Is written in other languages:
أوكسابروزين belongs to this group or family:
|VD||0.2 - 0.3||l/Kg|
|Tmax||2 - 4||hours|
|T½||50 - 55||hours|
Write us at firstname.lastname@example.org
e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Oxaprozin is a nonsteroidal anti-inflammatory drug (NSAID), derived from propionic acid, used to treat osteoarthritis and rheumatoid arthritis. Oral administration once daily.
Since the last update we have not found published data on its excretion in breastmilk.
Its pharmacokinetic data (very high percentage of protein binding and wide volume of distribution) make it highly unlikely that significant quantities will pass into breast milk.
Until more published data is known about this drug in relation to breastfeeding, known safer alternatives are preferable, especially during the neonatal period and in the event of prematurity.